mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity

AR function in promoting metastatic prostate cancer

(2014) Michael A. Augello et al.   CANCER AND METASTASIS REVIEWS

Metastatic Stem Cells: Sources, Niches, and Vital Pathways

(2014) Thordur Oskarsson et al.   Cell Stem Cell

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

(2014) Antonina V. Kurtova et al.   NATURE

Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells

(2013) R. Takahashi et al.   BIOMEDICINE & PHARMACOTHERAPY

 1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

(2013) W. S. Carbonell et al.   CANCER RESEARCH

Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2to promote tumor growth and to inhibit T cell activation

(2013) Weixiao Sha et al.   INTERNATIONAL JOURNAL OF CANCER

Differential stem- and progenitor-cell trafficking by prostaglandin E2

(2013) Jonathan Hoggatt et al.   NATURE

Validation of stem cell markers in clinical prostate cancer: α6-Integrin is predictive for non-aggressive disease

(2013) A. Marije Hoogland et al.   PROSTATE

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

(2013) L. M. Coussens et al.   SCIENCE

Molecular Pathogenesis and Progression of Prostate Cancer

(2013) Randy Schrecengost et al.   SEMINARS IN ONCOLOGY

NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128

(2013) R Nanta et al.   Oncogenesis

Expression and Significance of Microsomal Prostaglandin Synthase-1 (mPGES-1) and Beclin-1 in the Development of Prostate Cancer

(2012) Lu-Wei Xu et al.   Asian Pacific Journal of Cancer Prevention

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)

(2012) R. Cathomas et al.   CLINICAL CANCER RESEARCH

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The link between benign prostatic hyperplasia and prostate cancer

(2012) David D. Ørsted et al.   Nature Reviews Urology

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The cancer stem cell: premises, promises and challenges

(2011) Hans Clevers   NATURE MEDICINE

EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity

(2011) S Donnini et al.   ONCOGENE

Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis

(2011) D Lu et al.   ONCOGENE

α1 and β1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells

(2010) Satyanarayana Rentala et al.   ASIAN JOURNAL OF ANDROLOGY

Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis

(2009) Daisuke Kamei et al.   BIOCHEMICAL JOURNAL

Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature

(2009) George J. Klarmann et al.   CLINICAL & EXPERIMENTAL METASTASIS

Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells

(2009) H. Hanaka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

(2009) Chadi Nabhan et al.   UROLOGY

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

(2008) G. Gravis et al.   ANNALS OF ONCOLOGY

The epidermal growth factor receptor family: Biology driving targeted therapeutics

(2008) M. J. Wieduwilt et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

MF63 [2-(6-Chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation

(2008) D. Xu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE